Raja Devanathan, MD
Pulmonary Disease · Hobart, INNPI 1871587220
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $168,409 of the $192,640 with a category attached, or 87.4%. GSK accounts for 64.5% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $95,347 and has fallen 87.4% since, to $11,968 in 2025. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $512.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$124K
- AstraZeneca$41K
- Genentech USA, Inc.$15K
- Sunovion Pharmaceuticals Inc.$4K
- Novartis$4K
- Boehringer Ingelheim$1K
- plus $3K from 24 others
Across 51 payments — averaging $13,121 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$378K
- Verona Pharma, Inc.$110K
- Mylan Specialty L.p.$99K
- AstraZeneca$43K
- Chiesi USA, Inc.$22K
- Sanofi US Services Inc.$16K
- plus $2K from 1 others
What the payments were for
- Consulting fees$8,2504%
- Speaking & faculty fees$168,40987%
- Travel & lodging$6,4053%
- Food & beverage$9,3285%
- Education$2480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 211 | $124,256 |
| AstraZeneca | 57 | $41,006 |
| Genentech USA, Inc. | 22 | $15,315 |
| Sunovion Pharmaceuticals Inc. | 7 | $4,320 |
| Novartis | 9 | $3,605 |
| Boehringer Ingelheim | 2 | $1,066 |
| Johnson & Johnson(2 entities) | 8 | $710 |
| Inspire Medical Systems, Inc. | 6 | $447 |
| Actelion Pharmaceuticals US, Inc. | 6 | $332 |
| Amgen(2 entities) | 13 | $205 |
| Sanofi-aventis U.S. LLC | 2 | $162 |
| Insmed, Inc. | 5 | $150 |
| Regeneron Healthcare Solutions, Inc. | 2 | $147 |
| Intuitive Surgical | 1 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $127 |
| Jazz Pharmaceuticals Inc. | 1 | $107 |
| United Therapeutics Corporation | 2 | $100 |
| Bayer | 1 | $99 |
| Sanofi | 4 | $97 |
| Mylan Specialty L.p. | 3 | $56 |
| Philips North America LLC | 2 | $37 |
| AbbVie(2 entities) | 2 | $32 |
| CSL Behring | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
| Pulmonx Corporation | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Fisher & Paykel Healthcare Inc | 1 | $14 |
| Inogen, Inc. | 1 | $14 |
| Electromed, Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$77,084
- TRELEGY ELLIPTA$34,716
- FASENRA$20,550
- TEZSPIRE$19,450
- XOLAIR$18,003
- ANORO$4,420
- LONHALA MAGNAIR$4,104
- OFEV$1,050
- GILENYA$396
- Monarch Platform$274
- Inspire$242
- ANORO ELLIPTA$221
- Da Vinci Surgical System$127
- Arikayce$112
- XARELTO$110
- LIBTAYO$108
- XYWAV$107
- BREZTRI$100
How this compares
$192,640 in reported general payments places this provider in the 95th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 876 | $1,031,831 |
| XolairOmalizumab | 89 | $269,978 |
| NucalaMepolizumab | 55 | $231,009 |
| Breo ElliptaFluticasone/Vilanterol | 236 | $174,462 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 191 | $166,324 |
| Dupixent PenDupilumab | 30 | $126,482 |
| Ambrisentan | 20 | $124,478 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 11 | $100,244 |
| FasenraBenralizumab | 17 | $98,031 |
| Spiriva RespimatTiotropium Bromide | 61 | $53,301 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $42,739 |
| SymbicortBudesonide/Formoterol Fumarate | 70 | $33,994 |
| Spiriva HandihalerTiotropium Bromide | 39 | $27,345 |
| EliquisApixaban | 24 | $26,164 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 824 | $23,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $124,256 | $1,516,9161,282 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Symbicort, Daliresp | $41,006 | $310,736295 claims |
| PfizerPanzyga, Eliquis, Paxlovid | $13 | $129,26652 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $1,066 | $76,21482 claims |
| Johnson & JohnsonXarelto | $710 | $18,81125 claims |
| AbbVieLinzess | $32 | $17,00811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Hobart
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
- Rajeev MehtaMuncie$88K
- Gary ZalogaIndianapolis$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.